Dihydroergotamine (injection): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 1: Line 1:
__NOTOC__
{{Dihydroergotamine}}
{{CMG}}; {{AE}} {{PB}}


'''''For patient information about Dihydroergotamine, click [[Dihydroergotamine (patient information)|here]].'''''
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|aOrAn=a
|hasBlackBoxWarning=Yes
|adverseReactions=<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


{{SB}} MIGRANAL (dihydroergotamine mesylate) spray<sup>®</sup>, D.H.E. 45<sup>®</sup>, DIHYDROERGOTAMINE MESYLATE injection<sup>®</sup>
* Content


==Overview==
<!--Adult Indications and Dosage-->
{{drugbox
 
|IUPAC_name=
<!--FDA-Labeled Indications and Dosage (Adult)-->
|image= Dihydroergotamine.png
|fdaLIADAdult======Condition1=====
|CAS_number=511-12-6
 
|ATC_prefix=N02
* Dosing Information
|ATC_suffix=CA01
 
|ATC_supplemental=
:* Dosage
|PubChem=10531
 
|DrugBank=APRD00476
=====Condition2=====
|C=33|H=37|N=5|O=5
 
|molecular_weight=583.678 g/mol
* Dosing Information
|bioavailability=
 
|protein_bound=
:* Dosage
|metabolism=
 
|elimination_half-life=9 hours
=====Condition3=====
|excretion=
 
|pregnancy_AU=<!-- A / B1 / B2 / B3 / C / D / X -->
* Dosing Information
|pregnancy_US=<!-- A / B / C / D / X -->
 
|pregnancy_category=
:* Dosage
|legal_AU=<!-- Unscheduled / S2 / S4 / S8 -->
 
|legal_UK=<!-- GSL / P / POM / CD -->
=====Condition4=====
|legal_US=<!-- OTC / Rx-only -->
 
|legal_status=
* Dosing Information
|routes_of_administration=
 
}}
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


'''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s.
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


==Category==
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


==FDA Package Insert==
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


==MIGRANAL (dihydroergotamine mesylate) spray==
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>


'''  [[MIGRANAL (dihydroergotamine mesylate) spray indications and usage|Indications and Usage]]'''
<!--Look-Alike Drug Names-->
'''| [[MIGRANAL (dihydroergotamine mesylate) spray dosage and administration|Dosage and Administration]]'''
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
'''| [[MIGRANAL (dihydroergotamine mesylate) spray dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray contraindications|Contraindications]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray warnings and precautions|Warnings and Precautions]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray adverse reactions|Adverse Reactions]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray drug interactions|Drug Interactions]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray use in specific populations|Use in Specific Populations]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray overdosage|Overdosage]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray description|Description]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray clinical pharmacology|Clinical Pharmacology]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray clinical studies|Clinical Studies]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray patient counseling information|Patient Counseling Information]]'''
'''| [[MIGRANAL (dihydroergotamine mesylate) spray labels and packages|Labels and Packages]]'''


==D.H.E. 45 (dihydroergotamine mesylate) injection, solution==
<!--Drug Shortage Status-->
'''  [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution indications and usage|Indications and Usage]]'''
|drugShortage=
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution dosage and administration|Dosage and Administration]]'''
}}
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution dosage forms and strengths|Dosage Forms and Strengths]]'''
{{PillImage
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution contraindications|Contraindications]]'''
|fileName=No image.jpg
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution warnings and precautions|Warnings and Precautions]]'''
}}
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution adverse reactions|Adverse Reactions]]'''
{{LabelImage
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution drug interactions|Drug Interactions]]'''
|fileName={{PAGENAME}}11.png
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution use in specific populations|Use in Specific Populations]]'''
}}
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution overdosage|Overdosage]]'''
{{LabelImage
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution description|Description]]'''
|fileName={{PAGENAME}}11.png
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution clinical pharmacology|Clinical Pharmacology]]'''
}}
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution nonclinical toxicology|Nonclinical Toxicology]]'''
<!--Pill Image-->
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution clinical studies|Clinical Studies]]'''
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution patient counseling information|Patient Counseling Information]]'''
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution labels and packages|Labels and Packages]]'''


==Mechanism of Action==


'''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = MIGRANAL (DIHYDROERGOTAMINE MESYLATE) SPRAY [VALEANT PHARMACEUTICALS INTERNATIONAL] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a24befa8-b952-48ac-942a-379585250782 | publisher =  | date =  | accessdate = }}</ref> <ref>{{Cite web  | last =  | first =  | title = D.H.E. 45 (DIHYDROERGOTAMINE MESYLATE) INJECTION, SOLUTION [VALEANT PHARMACEUTICALS NORTH AMERICA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff | publisher =  | date =  | accessdate = }}</ref>


==References==
<!--Label Display Image-->


{{Reflist|2}}


[[Category:Drugs]]


{{Antimigraine preparations}}


[[Category:Lysergamides]]


[[pl:Dihydroergotamina]]
<!--Category-->


{{WH}}
[[Category:Drug]]
{{WS}}

Revision as of 21:18, 29 January 2015

Dihydroergotamine (injection)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Dihydroergotamine (injection) is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dihydroergotamine (injection) in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dihydroergotamine (injection) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Dihydroergotamine (injection) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dihydroergotamine (injection) in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dihydroergotamine (injection) in pediatric patients.

Contraindications

  • Condition1

Warnings

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Dihydroergotamine (injection) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dihydroergotamine (injection) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dihydroergotamine (injection) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dihydroergotamine (injection) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dihydroergotamine (injection) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Dihydroergotamine (injection) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dihydroergotamine (injection) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dihydroergotamine (injection) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dihydroergotamine (injection) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dihydroergotamine (injection) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dihydroergotamine (injection) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dihydroergotamine (injection) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dihydroergotamine (injection) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Dihydroergotamine (injection) in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Dihydroergotamine (injection) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Dihydroergotamine (injection) in the drug label.

Pharmacology

There is limited information regarding Dihydroergotamine (injection) Pharmacology in the drug label.

Mechanism of Action

Structure

File:Dihydroergotamine (injection)01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dihydroergotamine (injection) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Dihydroergotamine (injection) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dihydroergotamine (injection) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dihydroergotamine (injection) in the drug label.

How Supplied

Storage

There is limited information regarding Dihydroergotamine (injection) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dihydroergotamine (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dihydroergotamine (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Dihydroergotamine (injection) in the drug label.

Precautions with Alcohol

  • Alcohol-Dihydroergotamine (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Dihydroergotamine (injection)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Dihydroergotamine (injection)
 |Label Name=Dihydroergotamine (injection)11.png

}}

{{#subobject: 

 |Label Page=Dihydroergotamine (injection)
 |Label Name=Dihydroergotamine (injection)11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Dihydroergotamine_(injection)&oldid=1061206"